Navigation Links
Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Date:9/15/2011

endpoint (p-value 0.005) in the Company's previous Phase 3 study as a clinically significant outcome following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment). The SUPPORTS trial was conducted at major transplant centers throughout the US, Europe, and Australia. The trial was the subject of a Special Protocol Assessment (SPA) agreement that the Company reached with the US Food and Drug Administration (FDA). It was determined in a pre-specified interim analysis that this study was unlikely to achieve the primary efficacy objective.

orBec® was the subject of two prior randomized, double-blind, placebo-controlled clinical trials in acute GI GVHD. The first study was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center, which demonstrated statistical significance in its primary endpoint of controlling GI GVHD (p-value 0.02). The second study was a 129-patient pivotal Phase 3 multi-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the US and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only 5 patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139).  At one year post-randomization in the Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Five MinuteClinic walk-in medical ... Memphis metropolitan area. Three clinics opened in ... month. A fourth clinic will be added in Springfield ... Bartlett is expected to open October 22.  MinuteClinic ... in the United States . The ...
(Date:9/19/2014)... DIEGO , Sept. 19, 2014  Lpath, ... leader in bioactive lipid-targeted therapeutics, announced today that ... 3,605,042 registered shares of common stock and 3,605,042 ... combined purchase price for one registered share of ... one unregistered share of common stock will be ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Approximately ninety-one percent of dentists say patients complaining about dry ... survey conducted by the Academy of General Dentistry (AGD). ... decrease in salivary function. It affects approximately one in ... risk for tooth decay. During the Academy of General Dentistry,s ...
... Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... July 9, 2009 at 8:00 am EDT (5:00 am PDT). ... investigator of the trial will discuss results of the Company,s ... the Company,s plans for further development and related matters. ...
Cached Medicine Technology:Dry Mouth Linked to Prescription and Over the Counter Drugs 2Dry Mouth Linked to Prescription and Over the Counter Drugs 3Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2
(Date:9/19/2014)... (PRWEB) September 19, 2014 Famous Vancouver ... announced that it has now become a one-stop-solution for ... and businesses in Vancouver. The company has achieved this ... services to its customers. While there are many companies ... to have a single vendor who can offer all ...
(Date:9/19/2014)... Recently, Top10BestSEOHosting.com has compared many professional web ... Hosting and Bluehost are the best VPS suppliers ... most people, VPS (Virtual Private Server) is the ... many servers, each of which has the appearance ... computer,” the manager of Top10BestSEOHosting.com says. , ...
(Date:9/19/2014)... September 19, 2014 Top 10 ... recently announced that HostGator.com, GoDaddy and Bluehost are ... These companies are the most recommended suppliers for ... Europe to buy high quality Linux hosting (including ... ) is one of many top hosting companies ...
(Date:9/19/2014)... 19, 2014 Ticket Down has ... for her 2015 “Honeymoon” Tour. This popular ticket reseller ... savings at the checkout. , Ariana Grande 2015 Honeymoon Tour ... Center) , Feb. 28, 2015: Milwaukee, WI (BMO Harris Bradley ... Center) , March 03, 2015: Chicago, IL (Allstate Arena) , ...
(Date:9/19/2014)... York University researchers say a simple test that ... heightened risk for developing Alzheimer,s disease in a ... signs of dementia., Faculty of Health Professor Lauren ... the study asked the participants to complete four ... screen laptop computers. The test aimed at detecting ...
Breaking Medicine News(10 mins):Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2
... ABAX ), a medical products company manufacturing point-of-care blood,analysis ... 2008. , , Highlights for the third quarter ... $27.0 million, up 5% over last year,s comparable quarter., ... over last year,s, comparable quarter., ...
... underlying trait, but connection is vague, study says , , ... doesn,t decrease a woman,s risk of preterm birth, according ... a link. , As a result of those earlier ... pregnant women undergo dental "deep cleaning" (scaling and root ...
... and PALO ALTO, Calif., Jan. 29 ,Diagnosoft, Inc., ... that assists in diagnosis, staging and therapeutic monitoring ... $4 million in Series B,financing led by Technology ... intends to use the new capital to support ...
... 29 Mylan Inc. (Nasdaq: MYL ) today ... issuance, the company has declared its quarterly dividend of $16.25 ... and a liquidation preference of $1,000.00 per share) payable on ... as of Feb. 1, 2009.Mylan Inc., which provides products to ...
... Meditation Center of Los Angeles will present a program featuring ... an ancient practice of physical fitness, which has been used ... youthfulness in the body. The Level 1 & 2 ... Center for the Arts in Eagle Rock.The healing Taoist practice ...
... On February 19, 2009 at Noon CT, compliance and ... and Catholic Healthcare West will be discussing how companies ... stagnant or declining budgets. They will be participating ... and Ethics, Five Leaders, Five Industries, Ideas for Your ...
Cached Medicine News:Health News:Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009 2Health News:Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009 3Health News:Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009 4Health News:Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009 5Health News:Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009 6Health News:Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009 7Health News:Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009 8Health News:Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009 9Health News:Gum Disease Treatment Doesn't Cut Preterm Birth Risk 2Health News:Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO 2Health News:Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO 3Health News:Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO 4Health News:World-renowned Instructor of the Healing Practice of Qigong to Teach in Los Angeles Mar. 7 & 8 2Health News:Five Leaders From Five Industries to Tackle Concerns Over the Economy and Its Impact on Compliance and Ethics During Society of Corporate Compliance and Ethics and Health Care Compliance Association Audio/Web Conference 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: